For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 631 | |||
| General and administrative expenses | 614 | |||
| Operating loss | -1,245 | |||
| Total financial expense, net | -34 | |||
| Net loss and comprehensive loss | -1,279 | |||
| Basic EPS | 0.07 | |||
| Diluted EPS | 0.07 | |||
| Basic Average Shares | 19,551,719 | |||
| Diluted Average Shares | 19,551,719 | |||
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)